跳至內容

齊雷索韋

維基百科,自由的百科全書
齊雷索韋
臨床資料
商品名英語Drug nomenclatureZiresovir
法律規範狀態
法律規範
  • Investigational New Drug
識別資訊
  • N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-2H-1λ6,4-benzothiazepin-4-yl)-6-methylquinazolin-4-amine
CAS號1422500-60-4
PubChem CID
ChemSpider
UNII
化學資訊
化學式C22H25N5O3S
摩爾質量439.5
3D模型(JSmol英語JSmol
  • CC1=CC2=C(C=C1)N=C(N=C2NCC3(COC3)N)N4CCS(=O)(=O)C5=CC=CC=C5C4
  • InChI=1S/C22H25N5O3S/c1-15-6-7-18-17(10-15)20(24-12-22(23)13-30-14-22)26-21(25-18)27-8-9-31(28,29)19-5-3-2-4-16(19)11-27/h2-7,10H,8-9,11-14,23H2,1H3,(H,24,25,26)
  • Key:GAAICKUTDBZCMT-UHFFFAOYSA-N

齊雷索韋(ziresovir、RO-0529AK0529,化學式C22H25N5O3S)是一種抗病毒藥,被開發用於治療呼吸道合胞病毒感染。它作為一種融合抑制劑,在II期臨床試驗中顯示出較好的療效。[1][2]

參見

[編輯]

參考文獻

[編輯]
  1. ^ Zheng X, Gao L, Wang L, Liang C, Wang B, Liu Y, Feng S, Zhang B, Zhou M, Yu X, Xiang K, Chen L, Guo T, Shen HC, Zou G, Wu JZ, Yun H. Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor. J Med Chem. 2019 Jul 11;62(13):6003-6014. doi:10.1021/acs.jmedchem.9b00654 PMID 31194544
  2. ^ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67. PMID 30974127 doi:10.1016/j.antiviral.2019.04.006